Private Equity: One Company's Surprising Route toward Value Creation
This article was originally published in Start Up
Executive Summary
In an unusual twist, a biotech is turning to private equity for its initial institutional financing, in the belief that it will offer a better route to long-term value creation than venture capital.
You may also be interested in...
A Look Back at 2006: The Pipeline Challenge
Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.
A Look Back at 2006: The Pipeline Challenge
Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.
Big Pharma Outbids Public Investors: Step-Ups in Biopharma Exits
Biotechs exiting via selling out to Big Pharma have been averaging far higher multiples than those exiting via IPO.